CEDAR KNOLLS, N.J., Aug. 5 EmisphereTechnologies, Inc. (Nasdaq: EMIS) announced today that Novartis Pharma AG hasfinished recruitment for a multi-center Phase III study exploring the safetyand efficacy of Salmon Calcitonin and Emisphere's proprietary Eligen(R)Technology in the treatment of vertebral fractures in postmenopausal womenaged 60-80 with osteoporosis. The last of 4,500+ patients was recruited in thefinal week of June, and the three-year study will be conducted in North andSouth America, Europe and Asia.
Osteoporosis is a disease associated with a gradual thinning and weakeningof the bones, occurring most frequently in women after menopause. Thinner andweaker bones are increasingly susceptible to fractures. Untreatedpostmenopausal osteoporosis can lead to chronic back pain, disablingfractures, and lost mobility.
"This Phase III study provides yet another application of our Eligen(R)Technology in the fight against osteoporosis. Safe, effective and rapidtreatment will make a difference in the lives of millions of American womenwho are afflicted with the disease," said Michael V. Novinski, President andChief Executive Officer of Emisphere.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company that focuseson a unique and improved delivery of therapeutic molecules using its Eligen(R)Technology. These molecules and compounds could be currently available or indevelopment. Such molecules are usually delivered by injection; in many cases,their benefits are limited due to poor bioavailability, slow on-set of actionor variable absorption. The Eligen(R) Technology can be applied to the oralroute of administration as well other delivery pathways, such as buccal,rectal, inhalation, intra-vaginal or transdermal. The website is:www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by representativesof Emisphere relating to matters that are not historical facts (includingwithout limitation those regarding the timing or potential outcomes ofresearch collaborations or clinical trials, any market that might develop forany of Emisphere's product candidates and the sufficiency of Emisphere's cashand other capital resources) are forward-looking statements that involve risksand uncertainties, including, but not limited to, the likelihood that futureresearch will prove successful, the likelihood that any product in theresearch pipeline will receive regulatory approval in the United States orabroad, the ability of Emisphere and/or its partners to develop, manufactureand commercialize products using Emisphere's drug delivery technology,Emisphere's ability to fund such efforts with or without partners, and otherrisks and uncertainties detailed in Emisphere's filings with the Securitiesand Exchange Commission, including those factors discussed under the caption"Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615)filed on March 5, 2007 and our Quarterly Report on Form 10-Q for the quarterended March 31, 2007, filed on May 7, 2007.For further information contact: Bob Madison, Senior Director Corporate Communications 973-532-8001 or firstname.lastname@example.org Adam Friedman, Adam Friedman Associates 212-981-2529, extension 18 or email@example.com
SOURCE Emisphere Technologies, Inc.